ADMP News Alert Adamis Pharmaceuticl (ADMP) 5.17 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Adamis Pharmaceuticl (ADMP) 5.17 $ADMP

Adamis Pharmaceuticals to Present at Two Upcoming Conferences
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced that the Company is scheduled to present a company overview at two upcoming conferences.
ADMP: 5.17 (+0.06)

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 104.59 (+0.31), KBIO: 1.63 (-0.04), PFE: 31.42 (-0.03), ADMP: 5.17 (+0.06), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66), FPRX: 26.12 (+0.07)

Contraception - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/rzn2sh/contraception) has announced the addition of the "Contraception - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Contraception - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actavis - Adamis Pharmaceuticals - Agile - ANI - Antares - Bayer - Evofem - HRA Pharma - Hydra Biosciences - Intas - Ligand - Merck & Co - Orbis Biosciences - Pantarhei Bioscience - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/rz...traception
MRK: 57.46 (+0.25), ADMP: 5.17 (+0.06), TEVA: 57.09 (+0.33)

Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 34.96 (+0.78), CMRX: 36.80 (+0.70), CVM: 0.62 (+0.03), ADMP: 5.17 (+0.06), GNCA: 7.42 (-0.11)

Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
GlobeNewswire - Wed Oct 15, 8:35AM CDT
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a sales and marketing plan for the anticipated launch of its epinephrine pre-filled syringe for treatment of allergic reactions (Type I) including anaphylaxis.
ADMP: 5.17 (+0.06)

Market Maker Surveillance Report. IDN, VII, ISNS, DGLY, MGT, ADMP, Winning Stocks With Lowest Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Intellicheck Mobilisa Inc (NYSE:IDN), Vicon Industries Inc (NYSE:VII), Image Sensing Systems Inc (NASDAQ:ISNS), Digital Ally Inc (NASDAQ GLY), MGT Capital Investments Inc (NYSE:MGT), Adamis Pharmaceuticals Corp (NASDAQ:ADMP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
MGT: 0.60 (-0.01), ADMP: 5.17 (+0.06), ISNS: 2.77 (+0.04), VII: 1.83 (+0.38), DGLY: 15.62 (+0.82), IDN: 3.04 (+0.03)

Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
Marketwire - Tue Aug 26, 6:15AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board.
ADMP: 5.17 (+0.06)

Adamis Pharmaceuticals raises USD5m from private placement of convertible preferred stock
M2 - Wed Aug 20, 9:24AM CDT
Biopharmaceutical company Adamis Pharmaceuticals (NASDAQ:ADMP) revealed on Tuesday the issuance of 1,418,439 shares of Series A convertible preferred stock to a fundamental healthcare institutional fund for gross cash proceeds of about USD5m in a private placement.
ADMP: 5.17 (+0.06)

Adamis Pharmaceuticals Announces Private Placement
eTeligis - Tue Aug 19, 4:15PM CDT
SAN DIEGO, CA, United States, via ETELIGIS INC., 08/19/2014 - - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare institutional fund and received gross cash proceeds of approximately $5,000,000.The preferred stock is convertible into common stock at a conversion ratio of 1-to-1 at the option of the investor and has no preference to the common shares.The Company also issued to the investor warrants to purchase a number of shares of common stock equal to the number of shares of preferred stock purchased by the investor.The warrants, which are exercisable for a period of five years, have an exercise price of $3.40 per share and are callable for cash.
ADMP: 5.17 (+0.06)

Adamis Pharmaceuticals' NDA for EPINEPHRINE INJECTION, USP accepted for US FDA's review
M2 - Wed Jul 30, 5:42AM CDT
Biopharmaceutical company Adamis Pharmaceuticals (NASDAQ:ADMP) reported on Tuesday the US Food and Drug Administration's (FDA) acceptance of its New Drug Application (NDA) for EPINEPHRINE INJECTION, USP, 1:1000 for review for the emergency treatment of allergic reactions (Type I) including anaphylaxis.
ADMP: 5.17 (+0.06)

FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe
Marketwire - Tue Jul 29, 8:15AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (PFS), for the emergency treatment of allergic reactions (Type I) including anaphylaxis.
ADMP: 5.17 (+0.06)

Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
CHD: 80.16 (-0.37), PFE: 31.42 (-0.03), ADMP: 5.17 (+0.06), MYL: 56.97 (+0.39), JNJ: 104.59 (+0.31), ANIP: 55.24 (+1.79), MRK: 57.46 (+0.25), LPCN: 5.15 (+0.01), TEVA: 57.09 (+0.33)

Adamis Pharmaceuticals Announces Investor Update Live Webcast
Marketwire - Thu Jun 12, 7:10AM CDT
Adamis Pharmaceuticals Corp. (NASDAQ: ADMP) ("the Company" will host a live webcast on Monday, June 16, 2014 at 4:15pm ET to provide a business update concerning the Company's recent corporate developments. The Company's President and CEO, Dr. Dennis Carlo, will host the call.
ADMP: 5.17 (+0.06)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 92

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 52

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 28

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 89

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 81

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 43

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 67

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading

Top 5 Most Recently Viewed Articles

DexCom Faces Class Action Lawsuit Over Securities Fraud Claims

Updated Category News Views 104

Overview of the Class Action Against DexCom, Inc. Investors in DexCom, Inc. are currently navigating important developments as a class action lawsuit has been filed. This legal action involves serious allegations of securities fraud against the company. Shareholders who have purchased DexCom securities may be affected, raising important questions about financial integrity...

Continue Reading
Amaroq Minerals Announces AGM Results and Future Directions

Updated Category News Views 209

Amaroq Minerals Ltd. Annual General Meeting Results Amaroq Minerals Ltd. is proud to share the results from its recent Annual General Meeting (AGM), reflecting a robust commitment from shareholders in shaping the future direction of the company. Held in a welcoming atmosphere, the event focused on critical decisions that underscore the corporation's strategic objectives...

Continue Reading
Explore the Theme of Connection and Creation at CIFF 2026

Updated Category News Views 254

Exciting New Developments at CIFF 2026 CIFF, the China International Furniture Fair, is gearing up for its 57th edition in March 2026. With a fresh theme, "CONNECT • CREATE", the event reflects the dynamic landscape of the furniture industry. The fair will facilitate exceptional connections within the furniture supply chain, including production, distribution, and...

Continue Reading
SpaceX's Starship to Showcase Advanced Starlink Technologies

Updated Category News Views 545

SpaceX's Latest Milestone in Satellite Technology Elon Musk's company, SpaceX, is gearing up for an exciting upcoming test flight of its Starship launch vehicle. The mission's highlight is the planned deployment of 10 model Starlink satellites, marking a significant step in demonstrating SpaceX's prowess in the satellite launch industry. The Innovative Starlink Satellites...

Continue Reading
DATAMYTE Introduces AI Efficiency in Mobile Inspections for APQP

Updated Category News Views 354

Transforming Quality Inspections with AI at DATAMYTE DATAMYTE, a leader in manufacturing technology, is truly reshaping the way inspections are conducted in the industry. By utilizing its innovative DIGITAL CLIPBOARD mobile platform alongside the powerful DATAMYTE GPT Artificial Intelligence System, the company is redefining the manual processes traditionally associated...

Continue Reading